Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.
Saved in:
| Title: | Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. |
|---|---|
| Authors: | Levin N; Triphase Accelerator, San Diego, CA, USA., Spencer A; Alfred Health, Monash University, Melbourne, Australia., Harrison SJ; The Peter MacCallum Cancer Centre, Melbourne, Australia., Chauhan D; Dana Farber Cancer Institute, Boston, MA, USA., Burrows FJ; Triphase Accelerator, San Diego, CA, USA., Anderson KC; Dana Farber Cancer Institute, Boston, MA, USA., Reich SD; Triphase Accelerator, San Diego, CA, USA., Richardson PG; Dana Farber Cancer Institute, Boston, MA, USA., Trikha M; Triphase Accelerator, San Diego, CA, USA. |
| Source: | British journal of haematology [Br J Haematol] 2016 Sep; Vol. 174 (5), pp. 711-20. Date of Electronic Publication: 2016 May 09. |
| Publication Type: | Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1365-2141 |
|---|---|
| DOI: | 10.1111/bjh.14113 |
